Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

• Status: Unknown status
• Trial end date: 2016-03-01

Summary

The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

• Phase: Phase 3

Details

• Lead Sponsor: Agennix
• Treatments: Carboplatin; Lactoferrin; Paclitaxel; Talactoferrin alfa